What ПАСК Treats: Main Uses and Benefits

This medication is generally used to address infections caused by drug-resistant strains of Mycobacterium tuberculosis, which includes multi-drug resistant (MDR) and extensively drug-resistant (XDR) forms. Its application is relevant in conditions characterized by periods of heightened symptoms due to microbial persistence. By incorporating this agent into a multi-drug regimen, the therapy plays a role in managing the infection, and may assist with managing the underlying cause of the condition, contributing to the overall goal of long-term control.

The drug is further applied in clinical settings that involve treatment failure or patient intolerance to other antituberculosis agents. Its use is considered appropriate when supportive symptom management is needed, as it assists with maintaining functional stability by helping to address the source of systemic imbalance. The drug's availability in these contexts may assist with maintaining the regimen's integrity for both adult and pediatric populations.

“The medication is commonly used to help with the overall long-term strategy when the infection has proven resistant to initial treatments.”

---

Quick Fact: Relief for Systemic Imbalance

This agent is commonly used to help manage the overall symptom load linked to chronic, persistent bacterial activity, providing supportive relief when symptoms interfere with routine activities.

Regulatory References

1. European Medicines Agency summary

Eligibility Map: Who can and cannot use ПАСК (Para-aminosalicylic Acid)

This section details official regulatory information regarding which populations can and cannot use the tuberculosis medicine ПАСК (aminosalicylic acid), based strictly on contraindications and restricted use guidelines.

Eligibility Classification	Population/Condition	Regulatory Status
Contraindicated	Patients with known hypersensitivity to aminosalicylic acid or any component of the drug.	Must Not Use
Use Allowed (Generally)	Patients requiring treatment for the approved indications who have no contraindications.	Generally Allowed

Restrictions and Special Considerations

Official documents outline specific monitoring considerations for two groups:

• Condition-Specific Restriction: The drug is contraindicated in patients with known hypersensitivity to the active substance or its excipients.
• Lactation/Pediatric Population: Use of ПАСК during lactation results in low levels of the substance in breast milk, and it is generally not expected to cause adverse effects in a breastfed infant, especially if the infant is older than two months. However, for exclusively breastfed infants, monitoring is recommended due to the rare potential for adverse effects such as jaundice, gastrointestinal disturbances, hypokalemia, thrombocytopenia, and hemolysis. Use is generally permitted with caution and monitoring in this context.

Interactions with other medicines and products

The interaction profile for Aminosalicylic Acid (ПАСК) is defined by pharmacokinetic and pharmacodynamic constraints that can significantly alter the exposure or safety of co-administered medicines. All documented interactions are based on official government regulatory prescribing information.

Interaction Restrictions and Timing Rules

Co-administration with Diphenylhydramine is prohibited because regulatory documentation states it decreases the gastrointestinal absorption of Aminosalicylic Acid itself. To maintain the proper efficacy of other anti-tuberculosis agents, Aminosalicylate Sodium must be administered at least 6 hours apart from Rifampin.

Exposure-Altering and Pharmacodynamic Interactions

Aminosalicylic Acid may reduce the systemic exposure of several co-administered drugs and intensify toxicity with others:

Interacting Substance	Official Interaction Pattern
Digoxin	Reduced gastrointestinal absorption; monitoring of serum levels is necessary.
Tenofovir	Exposure is significantly decreased (approximately 3-fold reduction).
Oral Vitamin B12	Reduced absorption, leading to a risk of depletion and hematological abnormalities.
Ethionamide / Prothionamide	Co-administration may intensify the risk of adverse reactions, including gastrointestinal effects and potential hepatotoxicity.

This regulatory framework emphasizes managing these pharmacokinetic conflicts and pharmacodynamic risks, which define critical constraints for its use in multi-drug regimens.

The Mechanism of Aminosalicylic Acid (ПАСК)

The mechanism of Aminosalicylic Acid (ПАСК) is characterized by a highly targeted antimetabolite action, which results in the inhibition of Mycobacterium tuberculosis proliferation by interfering with its core genetic machinery. This action is bacteriostatic, meaning it inhibits growth rather than directly causing cell death.

Interference with Bacterial Folate Synthesis

ПАСК functions as a prodrug, which requires metabolic processing inside the bacterial cell by enzymes like Dihydropteroate Synthase (DHPS). This activation generates a false intermediate that then competitively inhibits the key enzyme Dihydrofolate Reductase (DHFR). This molecular blockade interferes with the targeted folate pathway, a process required for synthesizing the precursors of genetic material.

Cessation of Nucleic Acid Precursor Production

The inhibition of DHFR prevents the necessary regeneration of tetrahydrofolate ( THF), a critical cofactor required for the synthesis of purine and thymidylate—the building blocks for DNA and RNA. By shutting down the production of these essential precursors, the drug stops the bacterium from replicating its genetic material and successfully dividing, which results in the cessation of cellular reproduction.

The administration of ПАСК (Para-Aminosalicylic Acid) is strictly defined by established clinical protocols, focusing on its specialized oral route and precise dosing schedule. The medicine is supplied as 4 g gastro-resistant granules, intended solely for oral use as part of a long-term combination regimen.

Dosing and Frequency

The standard adult regimen involves a total daily dose that does not exceed 12 g, typically administered as 4 g per intake, three times per day (TID). For pediatric patients, the total daily dose is calculated on a weight-basis at 150 mg per kilogram of body weight per day, which is then divided into two or three daily administrations. Dosing adjustments may apply to adults with low body weight, where the total daily dose may be reduced to 4 g or 8 g. The full duration of use commonly extends to 24 months.

Administration Requirements

To ensure proper intake, the granules must be taken with food and require specific preparation: the contents of the sachet must be mixed with an acidic liquid (such as orange or tomato juice) or soft acidic food (like applesauce or yogurt). It is critical that the mixture be consumed immediately, and the granules must not be crushed or chewed to preserve the enteric coating. If a dose is missed, it should be skipped, and the user should proceed with the next scheduled dose; the dose must not be doubled.

Research Evidence / Overview of Studies for ПАСК (Aminosalicylic Acid)

---

Evidence for use in Multi-Drug Resistant Tuberculosis (MDR-TB) and XDR-TB

The clinical evidence for ПАСК focuses primarily on its use as a component within complex, multi-drug treatment plans for resistant forms of tuberculosis (TB). Since the strains studied were multi-drug resistant, leading to the drug being examined only as part of a combination, studies rarely examine it on its own.

Instead, researchers rely on large-scale analyses that pool data from many different reports, including systematic reviews and Individual Patient Data Meta-analyses (IPD-MA), along with observational cohort studies. These research tools were used to explore how regimens containing ПАСК were studied over the full course of therapy. Studies monitored key bacteriological outcomes, such as the time required for patients to achieve sputum culture conversion, a measurement used to assess changes in microbial activity. They also tracked endpoints, including rates of treatment completion and mortality.

The findings derived from these large syntheses help contextualize how groups of patients treated with these complex regimens were observed. However, because ПАСК is always given with several other drugs, researchers note that the certainty of the evidence for the total regimen's duration and final outcomes is officially described as being lower. The evidence for the total strategy is officially described as Moderate to Low due to the reliance on non-randomized data and the challenge of isolating this drug's specific contribution.

---

Historical Evidence in Preventing Drug Resistance

PАСК also has a historical role that influenced its inclusion in later TB treatment strategies. Early research explored a challenge encountered in TB treatment: the rapid development of bacterial resistance to initial drugs.

The evidence that described this combination approach comes from foundational Randomized Controlled Trials (RCTs) conducted in the mid-20th century. These trials were designed to assess the effect of incorporating ПАСК into combination therapy by examining the rate at which Mycobacterium tuberculosis developed resistance to companion drugs like streptomycin and isoniazid. The findings described patterns related to resistance development when PАСК was included in the combination regimen.

---

What is Still Uncertain About the Research for ПАСК

While the evidence contributes to the broader evidence landscape for resistant TB treatment, several research gaps and limitations have been identified by regulators and scientific bodies.

A core limitation is that comparative evidence for the medicine is lacking. Because it is rarely studied in isolation, the research does not determine whether an individual will respond similarly, and the specific, isolated contribution of ПАСК to the final outcomes of the complex regimen is not fully established. Additionally, data for certain groups, such as detailed pharmacokinetic information for the youngest patients, remains insufficient.

Key Studies & References

1. PASER (aminosalicylic acid) Granule, Delayed Release FDA Label (Regulatory context for combination therapy and mechanism notes)

Common questions about ПАСК (FAQ)

---

Q: Why is ПАСК sometimes used with other medicines?

Official information indicates that this medicine is typically used in combination with other agents. This strategy is used as part of a treatment plan to address the condition and is intended to help prevent the development of drug resistance in the targeted bacteria.

---

Q: What is the difference between ПАСК and other medicines used for the same purpose?

Regulatory classification places ПАСК as a second-line anti-mycobacterial medicine. This means it is generally reserved for use in patients who have drug-resistant forms of the condition or those who cannot tolerate the initial, first-line treatments.

---

Q: What risks are described for taking ПАСК while breastfeeding?

Regulatory documents state that the drug is excreted into human milk at low levels. Monitoring may be considered for exclusively breastfed infants, especially those under two months, due to the potential for rare adverse effects like jaundice, blood-related issues, or gastrointestinal disturbances.

---

Q: Does ПАСК require any special monitoring by a doctor, like blood tests?

Official labeling advises that doctors should evaluate renal (kidney) function both before and during therapy. For certain patient groups, such as older adults, monitoring of complete blood cell counts and platelet counts may be relevant.

---

Q: Are there different forms or brands of ПАСК available?

Yes, the active ingredient, aminosalicylic acid, is sold under multiple trade names, including Paser and Granupas. The medicine is available in various forms, such as enteric-coated granules, tablets, and a lyophilizate (a powder for solution).

---

Q: Can patients who have stopped taking ПАСК restart it later?

Regulatory information emphasizes that this medicine is associated with a risk of Hypersensitivity Reactions, which can be severe. The official labeling states that the drug is contraindicated if a patient has a known hypersensitivity to the drug.

---

Q: Why do some sources mention hearing changes with ПАСК?

Official safety labeling lists vestibular syndrome as a common adverse reaction. Vestibular syndrome involves disturbances in balance and the inner ear, which may be referenced alongside general changes like giddiness.

---

Q: Can ПАСК be taken by children?

Yes, the official prescribing information provides a weight-based dosage calculation for use in pediatric patients. The medicine is used in children who require treatment for the approved indications.

---

Q: Are there any specific foods to avoid while taking ПАСК?

The official administration guidance is that the granules must be taken with food and mixed with an acidic liquid or soft acidic food to aid proper intake. No specific common food groups are listed that must be strictly avoided.

---

Q: Does ПАСК interact with common over-the-counter pain relievers?

Because the medicine is chemically related to salicylates, combining it with other salicylates like aspirin (a common pain reliever) can increase the risk of irritation and bleeding in the stomach.

---

Q: Can I take vitamins or supplements while on ПАСК?

Official interaction information indicates that ПАСК may reduce the absorption of Oral Vitamin B12. This reduction carries a risk of depletion in the body and associated hematological (blood-related) changes.

---

Q: Is there a known interaction between ПАСК and alcohol?

Regulatory documents state that consuming alcohol while taking this medication can increase the risk of stomach bleeding. Therefore, official guidance is that alcohol should be avoided during treatment.

---

Q: Is ПАСК safe to use during pregnancy, based on official information?

Regulatory information classifies the drug under FDA Pregnancy Category C. The classification indicates the medicine is used during pregnancy only if clearly needed, after a determination that the potential benefits are perceived to outweigh the potential risks.

---

Q: Do older adults need a special evaluation before taking ПАСК?

Official labeling suggests that older patients may have an increased risk of blood-related side effects compared to younger patients. For this reason, close monitoring of blood cell counts may be relevant for this group during therapy.

---

Q: Is there a specific maximum duration for taking ПАСК described in official documents?

Official labeling states that the full duration of use commonly extends to 24 months as part of a combination regimen. It does not define a strict, absolute maximum duration for its use.

---

Q: Are there any genetic factors that affect how someone responds to ПАСК?

Official information notes that patients with the enzyme deficiency glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid the medicine. This is due to the potential risk of haemolysis (destruction of red blood cells).

---

Q: Does the time of day I take ПАСК matter?

The standard regimen is typically administered three times per day (TID) and must be taken with food. The focus of the guidance is on maintaining equal distribution of the doses and timing around meals.

---

Q: What is the risk of accidental overdose with ПАСК?

Accidental or acute overdose may lead to symptoms of salicylate toxicity, as described in regulatory documents. These symptoms can include changes in hearing (tinnitus), dizziness (vertigo), headache, and confusion. Severe intoxication may lead to serious events, which are subject to clinical assessment.

---

Q: Is it okay to store ПАСК in a pillbox with other medications?

Official storage requirements state the product must be kept in the original container and tightly closed, protected from light and air to maintain stability. The granules should not be used if they have turned dark brown or purple. Official rules require protection from light and air, and the product must be kept tightly closed in the original container to maintain stability.

How to Store and Dispose of PASK

The official storage requirements for PASK (Para-Aminosalicylic Acid) specify strict environmental controls to maintain product stability. The product must be stored at a temperature not exceeding 25 C (77 F).

Storage Conditions

Requirement	Official Labeled Condition
Temperature	Store not above 25 C
Protection	Must be protected from light and air (material is light sensitive)
Container	Keep in the original container and tightly closed
Stability Warning	Do not use if the granules have turned dark brown or purple (indicates degradation)
Child Safety	Keep out of the sight and reach of children

Disposal Instructions

Any unused or expired PASK product must be disposed of in accordance with local requirements. The medicine must not be emptied into drains or discarded into the environment via wastewater.